CODX - Co-Diagnostics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.49
-0.14 (-3.86%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.63
Open3.64
Bid0.00 x 1800
Ask0.00 x 800
Day's Range3.47 - 3.64
52 Week Range1.45 - 6.85
Volume30,980
Avg. Volume1,024,587
Market Cap43.019M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Co-Diagnostics Completes Submission of CE Mark Registration for Tuberculosis Screening Test

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ MTB Test technical file has been submitted for registration with the European Community, and that the CE marked in vitro diagnostic (“IVD”) is expected to be available for purchase early in August in markets that accept a CE mark as valid regulatory approval.

  • Business Wirelast month

    Co-Diagnostics, Inc. to Host Booth at CARPHA Conference

    Co-Diagnostics, Inc. (NASDAQ: CODX), (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that they will be hosting a booth at the 63rd Annual 2018 Caribbean Public Health Agency (CARPHA) Health Research Conference in St. Kitts & Nevis on June 14-16. Co-Diagnostics, Inc. CEO Dwight Egan remarked, “We are excited to be attending this important event following the recent advancement in our CoPrimers™ platform technology in multiplex tests for SNP detection and the announcement of our CoPrimer technology being used in a research project conducted by the Wang Group at Stanford University.

  • ACCESSWIRElast month

    Today's Research Reports on Stocks to Watch: Co-Diagnostics and Valeant Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 6, 2018 / Both Co-Diagnostics and Valeant Pharmaceuticals saw big gains on Tuesday despite one not even having any news. Co-Diagnostics leaped ahead after announcing an ...

  • Business Wirelast month

    Co-Diagnostics, Inc. Announces Advancement of Co-Primers™ Technology in Multiplex SNP Genotyping

    Co-Diagnostics, Inc. (CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today an advancement in the Company’s Co-Primer™ platform technology in multiplex tests for SNP detection, which allows for multiple targets to be identified in a single reaction without costly and time-consuming re-optimization of primers. SNP detection refers to finding small-scale but clinically-significant mutations in a given gene using real-time polymerase chain reaction (PCR) testing. Medical applications of SNP detection include identifying the presence of cancer cells or cell-free genetic material in a liquid or tissue biopsy, and to determine the distinct type of cancer involved.

  • ACCESSWIRElast month

    Today's Research Reports on Stocks to Watch: Co-Diagnostics and Jaguar Health

    NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Shares of Co-Diagnostics Inc. was exploding on Friday after the company announced its CoPrimer™ technology is being employed to achieve the objectives of a research ...

  • ACCESSWIRElast month

    Co-Diagnostics Shares Soar on Recent Developments, Technology Review

    NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Co-Diagnostics, Inc. (CODX), a molecular diagnostics company that intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It's been almost a year since CODX completed its IPO raising $7 million with an offering of 1.2 million shares at $6 a share. On Friday, June 1, 2018, CODX shares closed at $4.79 (+65.17%) on unusually high volume of 20.9 million shares traded.

  • Business Wire2 months ago

    Co-Diagnostics, Inc. Announces Participation in Research Project with Stanford University

    Co-Diagnostics, Inc. (CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that the Company’s CoPrimer™ technology is being employed to achieve the objectives of a research project conducted by the Wang Group at Stanford University. The purpose of the study is to develop more efficient methods to detect multiple genetic mutations in the EGFR (epidermal growth factor receptor) gene, including the most frequently occurring mutations in lung cancer, within a single reaction. The investigators have been conducting research into the subject using commercially available primers for several years, the results of which have previously been published, and contacted Co-Diagnostics to utilize the Company’s technology to further improve comprehensive detection methods of mutations that are known to cause cancer.

  • Business Wire3 months ago

    Co-Diagnostics CEO to Discuss Strategic Direction in a Lytham Partners’ Virtual Presentation and Fireside Chat Event on Thursday, April 19, 2018 at 2:00 pm ET

    Co-Diagnostics, Inc.  , a diagnostics company with a unique, proprietary platform for the development of molecular diagnostic testing, announced today that it will discuss the Company’s strategic direction and recent corporate developments on Thursday, April 19, 2018 at 2:00 pm ET  in a Lytham Partners’ Virtual Presentation and Fireside Chat.

  • Business Wire3 months ago

    Co-Diagnostics Files Initial Annual Report on Form 10-K and Updates Corporate Developments

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced the filing of its initial Annual Report on Form 10-K as a public company.

  • Business Wire4 months ago

    Co-Diagnostics, Inc. Announces Construction Update at JV Manufacturing Facility in India

    Co-Diagnostics, Inc.  , a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today an update on the Joint Venture manufacturing facility in Vadodara, India.

  • Business Wire5 months ago

    Co-Diagnostics Inc Announces Positive Results from Co-Primers™ Technology in Multiplex Tests for SNP Detection

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that ongoing research and development activities of the Company’s Co-Primer™ platform technology has yielded positive results in demonstrating the capabilities of Co-Primers in multiplex tests for SNP detection.

  • Business Wire5 months ago

    Co-Diagnostics, Inc. Ships Product to India for Validation Study

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today a product shipment to India containing tests to be sold as Research Use Only as well as others to be used in validation studies in that country.

  • Business Wire6 months ago

    Co-Diagnostics, Inc. Initiates Vector Control Program in Dominican Republic

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today the completion of a sales and validation trip to the Dominican Republic, including the initiation of a vector control diagnostics program to track the spread and distribution of tropical diseases across mosquito populations.

  • Business Wire7 months ago

    Co-Diagnostics, Inc. Enters Into Lease for New, Upgraded Laboratory Facility

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today leasing a new and upgraded, CGMP-ready and Biological Safety Level 2 laboratory facility in Salt Lake City, Utah.

  • Business Wire7 months ago

    Co-Diagnostics, Inc. Announces Sale of Molecular Diagnostic Tests, Including Zika Virus, to Major Caribbean Laboratory

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that a major laboratory in the Caribbean Basin has completed its first purchase of the Company’s tests.

  • Business Wire8 months ago

    Co-Diagnostics, Inc. to Present at the Lytham Partners Virtual Investor Conference on November 30, 2017 at 2:00 p.m. ET

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced that Dwight Egan, chief executive officer of Co-Diagnostics, will present at the Lytham Partners Virtual Investor Conference on Thursday, November 30, 2017 at 2:00 p.m.

  • How Does Co-Diagnostics Inc (CODX) Compare To The Healthcare Sector?
    Simply Wall St.8 months ago

    How Does Co-Diagnostics Inc (CODX) Compare To The Healthcare Sector?

    Co-Diagnostics Inc (NASDAQ:CODX), a USD$63.50M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasing prevalenceRead More...

  • Business Wire8 months ago

    Co-Diagnostics, Inc. Reports Q3 Financial Results and Updates Corporate Developments

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced corporate developments and financial results for the third quarter of 2017, ended September 30, 2017.

  • Who Owns Co-Diagnostics Inc (CODX)?
    Simply Wall St.9 months ago

    Who Owns Co-Diagnostics Inc (CODX)?

    In this analysis, my focus will be on developing a perspective on Co-Diagnostics Inc’s (NASDAQ:CODX) latest ownership structure, a less discussed, but important factor. Ownership structure of a company hasRead More...

  • Business Wire9 months ago

    Co-Diagnostics, Inc. to Present Zika Tests to Dominican Republic Ministry of Health

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today upcoming meetings with the Ministry of Public Health and Social Assistance of the Dominican Republic to discuss the Company’s products.

  • Business Wire10 months ago

    Co-Diagnostics, Inc. to Present at Robins Equity Research Roundup 2017

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that it will be presenting at the Third Annual Robins Equity Research Roundup, held September 25 – 27, 2017 near Portland, Oregon.

  • Business Wire10 months ago

    Co-Diagnostics, Inc. to Present at NewsMakers Conference 2017

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that CEO Dwight Egan will represent Co-Diagnostics as a Presenting Company at the 24th Annual Biocentury NewsMakers in the Biotech Industry conference, held on September 8 in New York City.

  • Business Wire10 months ago

    Co-Diagnostics, Inc. to Sign Purchase Agreement with MEDCIS Pathlabs

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, and MEDCIS Pathlabs India Pvt.

  • Business Wire11 months ago

    Co-Diagnostics, Inc. Strengthens Zika Customer Base in Caribbean Basin

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that they have strengthened relationships with key regional customers throughout the Caribbean basin to purchase the Company’s Zika virus diagnostic.

  • Business Wire11 months ago

    Co-Diagnostics, Inc. CEO to Present at 2017 SALSS

    Co-Diagnostics, Inc.  , a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that CEO Dwight Egan will be a presenter at the 2017 Swedish-American Life Science Summit , taking place August 23-25 in Stockholm, Sweden.